04:16 PM EST, 11/14/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) reported a Q3 loss late Thursday of 1.72 euros ($1.81) per diluted share, narrower than a loss of 2.88 euros loss a year earlier.

Analysts polled by Capital IQ expected a loss of 1.46 euros.

Revenue for the quarter that ended Sept. 30 was 57.8 million euros, up from 48 million euros a year earlier.

Analysts surveyed by Capital IQ expected 70.3 million euros.

Shares of the company were about 8% lower in recent after-hours activity.

Price: 114.50, Change: -9.78, Percent Change: -7.87